JP2023549341A5 - - Google Patents

Info

Publication number
JP2023549341A5
JP2023549341A5 JP2023527451A JP2023527451A JP2023549341A5 JP 2023549341 A5 JP2023549341 A5 JP 2023549341A5 JP 2023527451 A JP2023527451 A JP 2023527451A JP 2023527451 A JP2023527451 A JP 2023527451A JP 2023549341 A5 JP2023549341 A5 JP 2023549341A5
Authority
JP
Japan
Prior art keywords
pyrazino
piperidine
methyl
hydroxyphenyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058424 external-priority patent/WO2022099117A1/en
Publication of JP2023549341A publication Critical patent/JP2023549341A/ja
Publication of JP2023549341A5 publication Critical patent/JP2023549341A5/ja
Pending legal-status Critical Current

Links

JP2023527451A 2020-11-06 2021-11-08 Brm標的化化合物及び関連する使用方法 Pending JP2023549341A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110688P 2020-11-06 2020-11-06
US63/110,688 2020-11-06
PCT/US2021/058424 WO2022099117A1 (en) 2020-11-06 2021-11-08 Brm targeting compounds and associated methods of use

Publications (2)

Publication Number Publication Date
JP2023549341A JP2023549341A (ja) 2023-11-24
JP2023549341A5 true JP2023549341A5 (enExample) 2024-11-18

Family

ID=81456756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527451A Pending JP2023549341A (ja) 2020-11-06 2021-11-08 Brm標的化化合物及び関連する使用方法

Country Status (10)

Country Link
US (1) US12448389B2 (enExample)
EP (1) EP4240743A1 (enExample)
JP (1) JP2023549341A (enExample)
KR (1) KR20230117577A (enExample)
CN (1) CN116745295A (enExample)
AU (1) AU2021376415A1 (enExample)
CA (1) CA3200685A1 (enExample)
IL (1) IL302669A (enExample)
MX (1) MX2023005301A (enExample)
WO (1) WO2022099117A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867554B (zh) * 2020-06-09 2025-09-02 普莱鲁德疗法有限公司 Brm靶向化合物和相关使用方法
JP7723743B2 (ja) * 2020-11-20 2025-08-14 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
JP2024512501A (ja) 2021-03-19 2024-03-19 アルヴィナス・オペレーションズ・インコーポレイテッド インダゾール系化合物及び関連使用方法
CA3235512A1 (en) * 2021-10-22 2023-04-27 Xiaobao Yang Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
WO2023178181A1 (en) * 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2023269778A1 (en) * 2022-05-10 2024-12-12 Prelude Therapeutics Incorporated 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
CN120282966A (zh) * 2022-09-15 2025-07-08 普莱鲁德疗法有限公司 Brm靶向化合物和相关使用方法
JP2025538228A (ja) 2022-11-15 2025-11-26 プレリュード・セラピューティクス・インコーポレイテッド Brm標的化化合物及び関連する使用方法
WO2024192064A1 (en) * 2023-03-14 2024-09-19 Oncopia Therapeutics, Inc. D/B/A/ Proteovant Therapeutics, Inc. Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024208300A1 (zh) * 2023-04-07 2024-10-10 南京再明医药有限公司 Brm选择性降解剂化合物
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
EP4727541A2 (en) * 2023-06-16 2026-04-22 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
TW202515874A (zh) 2023-09-28 2025-04-16 美商亞文納營運公司 用於靶向降解富含白胺酸之重複激酶2(lrrk2)的基於苯并咪唑及苯并咪唑酮之protac化合物
WO2025101738A1 (en) * 2023-11-07 2025-05-15 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
CN120548310A (zh) * 2023-12-26 2025-08-26 标新生物医药科技(上海)有限公司 具有双氮杂环取代的异吲哚啉酮骨架的化合物及其应用
WO2025184459A1 (en) * 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
US20250276074A1 (en) 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025194405A1 (en) * 2024-03-21 2025-09-25 Prelude Therapeutics Incorporated Polymorphic smarca inhibitors and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
US20190300521A1 (en) 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
EP3784665A4 (en) * 2018-04-26 2022-01-26 Aurigene Discovery Technologies Limited PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS
US11771697B2 (en) * 2018-04-30 2023-10-03 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (PBRM1)
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
CN115867554B (zh) 2020-06-09 2025-09-02 普莱鲁德疗法有限公司 Brm靶向化合物和相关使用方法
AU2023269778A1 (en) * 2022-05-10 2024-12-12 Prelude Therapeutics Incorporated 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2023549341A5 (enExample)
JP7313354B2 (ja) Tlr阻害剤として有用なアミド置換されたインドール化合物
US12233062B2 (en) Heterocyclic derivatives useful as SHP2 inhibitors
US12448389B2 (en) BRM targeting compounds and associated methods of use
TWI689510B (zh) 4-氮雜吲哚化合物
AU2011217286B2 (en) Pyrrolopyrimidine compounds as inhibitors of CDK4/6
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
CN113795483A (zh) 作为shp2拮抗剂的甲酰胺-嘧啶衍生物
IL280331B2 (en) Heterobicyclic compounds for inhibiting the activity of shp2
AU2018239542A1 (en) Novel heterocyclic derivatives useful as SHP2 inhibitors
KR20200100760A (ko) 디아자인돌 화합물
WO2019028301A1 (en) INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL
KR20200100687A (ko) 치환된 인돌 에테르 화합물
TW202330548A (zh) 用於降解egfr激酶的化合物
CN116981661A (zh) 稠环取代的六元杂环化合物及其制法和用途
US12091426B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
WO2021087181A1 (en) Substituted pyrazole compounds as toll receptor inhibitors
JP6454346B2 (ja) 芳香族複素環式化合物及び医薬におけるその応用
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
CN115557946A (zh) 杂环内酰胺类化合物,包含其的药物组合物及其用途
WO2025253326A1 (ko) Kras 저해제로서 신규한 3환 화합물 및 이의 용도
JP2025530791A (ja) トリアジン化合物及びその使用
EA052189B1 (ru) Соединения, нацеленные на brm, и связанные с ними способы использования